Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics Inc (NQ: MRSN )

4.450 -0.180 (-3.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 916,564
Open 4.580
Bid (Size) 4.440 (44)
Ask (Size) 4.450 (41)
Prev. Close 4.630
Today's Range 4.300 - 4.660
52wk Range 2.680 - 14.80
Shares Outstanding 71,761,525
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Recap: Mersana Therapeutics Q1 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-30.90%
-30.90%
1 Month
+33.23%
+33.23%
3 Month
+5.70%
+5.70%
6 Month
-23.41%
-23.41%
1 Year
-66.62%
-66.62%

More News

Read More
Earnings Scheduled For February 28, 2022
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Overview
Via Benzinga
Executives Buy Around $17M Of 5 Penny Stocks
Via Benzinga
Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Earnings Scheduled For May 9, 2022
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Looking Into Mersana Therapeutics's Return On Capital Employed
Via Benzinga
Recap: Mersana Therapeutics Q4 Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
78 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
60 Biggest Movers From Yesterday
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Via Benzinga
Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.